Alejandra Ortiz-Ruiz

9PUBLICATIONS
49CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsPredictive and prognostic markersHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Nov 13, 2025
The Potential of the Gut Microbiota and Butyrate to Enhance CAR T-cell Therapy in Non-Hodgkin Lymphoma.

Roberto García-Vicente, Alba Rodríguez-García, Raquel Ancos-Pintado

|Dec 22, 2023
Impaired FADD/BID signaling mediates cross-resistance to immunotherapy in Multiple Myeloma.

Umair Munawar, Xiang Zhou, Sabrina Prommersberger

|Jul 08, 2023
Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia.

María Luz Morales, Roberto García-Vicente, Alba Rodríguez-García

|Aug 15, 2021
NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma.

Alejandra Leivas, Antonio Valeri, Laura Córdoba

|Jul 02, 2021
Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma.

Yanira Ruiz-Heredia, Alejandra Ortiz-Ruiz, Mehmet K Samur

|Apr 30, 2021
Myc-Related Mitochondrial Activity as a Novel Target for Multiple Myeloma.

Alejandra Ortiz-Ruiz, Yanira Ruiz-Heredia, María Luz Morales

Pageof 2